CB-5083: Unraveling ER-Associated Protein and Lipid Homeostasis in Cancer Research

Introduction

The disruption of cellular protein and lipid homeostasis is a defining hallmark of cancer progression and therapeutic vulnerability. Central to these intersecting regulatory networks is the AAA-ATPase p97 (valosin-containing protein, VCP), a molecular chaperone orchestrating protein degradation, endoplasmic reticulum-associated degradation (ERAD), and organelle membrane dynamics. CB-5083 (SKU: B6032) has emerged as a highly selective, orally bioavailable p97 inhibitor, enabling unprecedented mechanistic dissection of proteostasis and ER lipid regulation in oncology and beyond. While previous reviews, such as 'CB-5083: Precision Modulation of Protein Degradation and ...', focus on CB-5083's utility in protein homeostasis and apoptosis, this article integrates recent advances in ER lipid-protein interplay and highlights new research frontiers, building a unique bridge between cancer cell death mechanisms and metabolic regulation.

CB-5083: Chemical Properties and Formulation

CB-5083 is a solid compound with the molecular formula C₂₄H₂₃N₅O₂ and a molecular weight of 413.47 g/mol. It is insoluble in water but readily dissolves in DMSO (>20.65 mg/mL) and ethanol (>4.4 mg/mL), facilitating diverse in vitro and in vivo applications. For optimal experimental performance, CB-5083 stock solutions should be stored at -20°C, with warming and ultrasonic agitation recommended to enhance solubility. Importantly, the compound is supplied for research use only, excluding diagnostic or therapeutic applications.

The Central Role of p97 in Cellular Homeostasis

p97/VCP is a highly conserved AAA-ATPase that orchestrates a spectrum of cellular processes, notably ERAD-mediated protein turnover, organelle membrane fusion, and endosomal cargo sorting. By regulating the extraction and proteasomal targeting of poly-ubiquitinated proteins from the ER membrane, p97 maintains proteostasis under basal and stress conditions. This activity is intimately tied to the unfolded protein response (UPR), which is activated upon accumulation of misfolded proteins within the ER. Notably, p97 also interfaces with lipid metabolic enzymes, modulating ER membrane expansion and lipid droplet biogenesis, as elucidated in recent work (Carrasquillo Rodríguez et al., 2024).

Mechanism of Action of CB-5083: Selective Disruption of the Protein Degradation Pathway

CB-5083 is a first-in-class, high-affinity oral bioavailable p97 inhibitor that acts by selectively competing with ATP at the D2 ATPase domain of p97 (IC₅₀ = 15.4 nM for wild-type p97). This targeted inhibition abrogates the unfolding and extraction of poly-ubiquitinated substrates from the ER membrane, leading to their cytoplasmic accumulation. In preclinical models, CB-5083 induces a dose-dependent increase in TCRα-GFP retention in the ER and accumulation of poly-ubiquitinated proteins across multiple cancer cell lines (e.g., HEK293T, A549, HCT116). This proteostatic imbalance triggers UPR activation and downstream apoptosis via the caspase signaling pathway, culminating in potent cancer cell death and tumor growth inhibition in xenograft models.

Integrating Protein and Lipid Homeostasis: Insights from Recent Research

While the cytotoxic effects of CB-5083 primarily result from protein homeostasis disruption and UPR-mediated apoptosis, a growing body of evidence positions the ER as a nexus for both protein and lipid regulation. The reference study by Carrasquillo Rodríguez et al. (2024) illuminates the dual roles of CTD-NEP1, an ER-localized phosphatase, and its regulatory partner NEP1R1, in modulating lipin 1 activity and ultimately dictating the balance between ER membrane expansion and lipid droplet storage. This regulation is crucial for maintaining lipid homeostasis under fluctuating metabolic demands. Notably, p97's established role in ERAD and proteasomal degradation provides a mechanistic link to these newly appreciated lipid regulatory circuits, suggesting that p97 inhibition by CB-5083 may exert pleiotropic effects on both proteostasis and lipid metabolism in cancer cells.

CB-5083 and the Unfolded Protein Response (UPR)

The accumulation of misfolded and poly-ubiquitinated proteins caused by CB-5083 leads to robust activation of the UPR, a stress response pathway that attempts to restore ER homeostasis. If unresolved, UPR activation transitions from a protective mechanism to one that induces apoptosis via CHOP upregulation and caspase activation. This cascade is central to CB-5083’s cancer cell apoptosis induction, differentiating it from other proteasome-targeting agents by its unique upstream blockade at the p97 level.

Implications for Lipid Metabolism and ER Expansion

The interplay between protein and lipid homeostasis is increasingly recognized as a determinant of cancer cell adaptability. The reference article demonstrates that stabilization of CTDNEP1 by NEP1R1 restricts ER membrane synthesis, a process intimately linked to lipid availability and ER function. Since p97 function is essential for the extraction of certain membrane proteins and lipid regulatory enzymes, its inhibition by CB-5083 could indirectly modulate the ER’s capacity for lipid synthesis and storage. This represents a compelling avenue for further research, particularly in cancers exhibiting deregulated lipid metabolism.

Comparative Analysis: CB-5083 Versus Alternative Approaches

While proteasome inhibitors such as bortezomib disrupt protein degradation at the level of the 26S proteasome, CB-5083 acts upstream by targeting p97, a key mediator of substrate extraction from the ER membrane. This mechanistic distinction positions CB-5083 as a tool for dissecting ER-associated degradation with greater specificity. Compared to other p97 inhibitors, CB-5083’s potent oral bioavailability and selectivity for the D2 ATPase domain confer advantages for both in vitro mechanistic studies and translational research.

Previous reviews, such as 'CB-5083: Targeting p97 AAA-ATPase to Disrupt Protein Home...', provide foundational overviews of CB-5083’s anticancer mechanisms. Here, we go further by integrating emerging data on ER lipid regulation and highlighting the compound’s potential to probe the nexus of protein and lipid homeostasis—a research direction underrepresented in earlier literature.

Advanced Applications in Cancer and Metabolic Disease Research

CB-5083 in Multiple Myeloma and Solid Tumor Models

Preclinical and early clinical studies have demonstrated that oral administration of CB-5083 produces significant tumor growth inhibition in xenograft models of colorectal adenocarcinoma, non-small-cell lung cancer, and multiple myeloma, with tumor growth inhibition (TGI) rates up to 63%. The compound’s ability to induce ER stress, activate the UPR, and trigger apoptosis via the caspase signaling pathway positions it as a valuable tool for dissecting cell death mechanisms in hematologic and solid malignancies. Ongoing phase 1 clinical trials further underscore its translational promise for multiple myeloma research and solid tumor research.

Exploring Protein-Lipid Crosstalk and ER Homeostasis

Recent discoveries, as highlighted in the reference study, indicate that the ER’s ability to balance membrane expansion and lipid storage is governed by phosphatase and regulatory subunit interactions (CTDNEP1-NEP1R1), with proteasomal degradation modulating their stability. The intersection of CB-5083’s inhibition of the protein degradation pathway and the lipid regulatory axis provides a unique experimental platform to interrogate how protein and lipid homeostasis are co-regulated under stress and in cancer. This approach diverges from prior analyses (see 'CB-5083: Disrupting p97 to Unravel ER Lipid-Protein Inter...'), which primarily review mechanistic insights without deeply integrating the latest findings on CTDNEP1-NEP1R1 and lipid homeostasis.

Beyond Oncology: Metabolic and Neurodegenerative Implications

Given the centrality of ER-associated degradation and lipid regulation in metabolic syndromes and neurodegenerative diseases, CB-5083’s precise targeting of p97 positions it as a candidate for exploring pathogenic mechanisms beyond cancer. By modulating the ER’s capacity for both proteostasis and membrane expansion, researchers can employ CB-5083 to investigate the molecular underpinnings of diseases characterized by ER stress and lipid dysregulation.

Conclusion and Future Outlook

CB-5083 stands at the forefront of research tools for dissecting the intricate balance between protein degradation and lipid homeostasis within the ER. Its selective and potent inhibition of p97 not only induces cancer cell apoptosis through classical UPR activation but also enables novel exploration of lipid regulatory circuits, as described in recent advances on CTDNEP1-NEP1R1 function (Carrasquillo Rodríguez et al., 2024). Moving beyond existing reviews—such as 'CB-5083: Advanced Insights into Selective p97 Inhibition ...', which focus predominantly on translational oncology—this article emphasizes the integrative research possibilities of CB-5083 in both cancer and metabolic disease models. For investigators seeking to unravel the complex crosstalk between protein quality control and lipid metabolism, CB-5083 offers a uniquely powerful platform for discovery.